Thirona licenses patent for cystic fibrosis AI software

By staff writers

October 6, 2020 -- Dutch artificial intelligence (AI) software developer Thirona said it has exclusively licensed a patent that will enable development of an automated method for detecting and quantifying the extent of lung disease on CT scans in patients with cystic fibrosis.

The AI algorithm will build on PRAGMA-CF, a quantitative image analysis method for pediatric chest CT exams previously developed by researchers at the Erasmus University Medical Center Rotterdam in the Netherlands and the Telethon Kids Institute in Australia. Although PRAGMA-CF can be used to manually assess the extent of cystic fibrosis in children with cystic fibrosis (CF), the current technique is time-consuming and requires extensive training, according to Thirona.

Via the exclusive license, Thirona will integrate the PRAGMA-CF method into its LungQ software. The company has also secured co-exclusive rights to utilize the underlying datasets of PRAGMA-CF in order to develop their AI algorithm. The model will be designed to detect bronchiectasis and mucous quantifications in very young patients with CF, making it easier to provide personalized treatment, according to the vendor.

Thirona, Smart Reporting team up on COVID-19 software
Dutch artificial intelligence software developer Thirona has partnered with software developer Smart Reporting to create software that enhances COVID-19...
Thirona unveils AI software for COVID-19 analysis
Dutch artificial intelligence (AI) software developer Thirona has introduced two free software applications to assist in the triage of suspected COVID-19...
German start-up wins grant for deep-learning project
Munich-based start-up company Smart Reporting has received a multimillion euro grant from the Eurostars funding program to support development of its...

Copyright © 2020

Last Updated mf 10/6/2020 10:13:40 AM